Imbria Pharmaceuticals Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $66.7M

  • Investors
  • 8

Imbria Pharmaceuticals General Information

Description

Operator of a clinical-stage company designed to develop novel therapies for patients with life-altering cardiometabolic disorders. The company focused on restoring or improving the cell's ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits in non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction, enabling healthcare providers to provide medicine by altering the cellular metabolism and mitochondrial function.

Contact Information

Website
www.imbria.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 265 Franklin Street
  • Suite 1702
  • Boston, MA 02116
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 265 Franklin Street
  • Suite 1702
  • Boston, MA 02116
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Imbria Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 16-Dec-2025 $66.7M Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 22-Jul-2020 Completed Clinical Trials - Phase 2
1. Seed Round 02-Jul-2018 $40.2M $40.2M Completed Clinical Trials - Phase 2
To view Imbria Pharmaceuticals’s complete valuation and funding history, request access »

Imbria Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-3
Series B-2
Series B-1
Series A
Seed-1 13,639,285 $0.000100 $2.65 $2.65 1x $2.62 9.22%
Seed 8,473,683 $0.000100 $4.75 $4.75 1x $4.75 5.66%
To view Imbria Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Imbria Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage company designed to develop novel therapies for patients with life-altering cardiometabolic
Drug Discovery
Boston, MA
10 As of 2025

South San Francisco, CA
 

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Imbria Pharmaceuticals Competitors (4)

One of Imbria Pharmaceuticals’s 4 competitors is Cytokinetics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cytokinetics Formerly VC-backed South San Francisco, CA
Altimmune Formerly VC-backed Gaithersburg, MD
Gossamer Bio Formerly VC-backed San Diego, CA
Milestone Pharmaceuticals Formerly VC-backed Montreal, Canada
To view Imbria Pharmaceuticals’s complete competitors history, request access »

Imbria Pharmaceuticals Patents

Imbria Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4531845-A1 Compounds and methods for increasing efficiency of cardiac metabolism Pending 03-Jun-2022
EP-4531845-A4 Compounds and methods for increasing efficiency of cardiac metabolism Pending 03-Jun-2022
US-20250340523-A1 Compounds and methods for increasing efficiency of cardiac metabolism Pending 03-Jun-2022
WO-2023235297-A1 Compounds and methods for increasing efficiency of cardiac metabolism Inactive 03-Jun-2022
AU-2022376557-A1 Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism Pending 01-Nov-2021 A61K31/496
To view Imbria Pharmaceuticals’s complete patent history, request access »

Imbria Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Imbria Pharmaceuticals Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
AN Venture Partners Venture Capital Minority
Catalio Capital Management Venture Capital Minority
Cytokinetics Corporation Minority
Deep Track Capital Venture Capital Minority
SV Health Investors PE/Buyout Minority
You’re viewing 5 of 8 investors. Get the full list »

Imbria Pharmaceuticals FAQs

  • When was Imbria Pharmaceuticals founded?

    Imbria Pharmaceuticals was founded in 2018.

  • Where is Imbria Pharmaceuticals headquartered?

    Imbria Pharmaceuticals is headquartered in Boston, MA.

  • What is the size of Imbria Pharmaceuticals?

    Imbria Pharmaceuticals has 10 total employees.

  • What industry is Imbria Pharmaceuticals in?

    Imbria Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Imbria Pharmaceuticals a private or public company?

    Imbria Pharmaceuticals is a Private company.

  • What is the current valuation of Imbria Pharmaceuticals?

    The current valuation of Imbria Pharmaceuticals is .

  • What is Imbria Pharmaceuticals’s current revenue?

    The current revenue for Imbria Pharmaceuticals is .

  • How much funding has Imbria Pharmaceuticals raised over time?

    Imbria Pharmaceuticals has raised $152M.

  • Who are Imbria Pharmaceuticals’s investors?

    AN Venture Partners, Catalio Capital Management, Cytokinetics, Deep Track Capital, and SV Health Investors are 5 of 8 investors who have invested in Imbria Pharmaceuticals.

  • Who are Imbria Pharmaceuticals’s competitors?

    Cytokinetics, Altimmune, Gossamer Bio, and Milestone Pharmaceuticals are competitors of Imbria Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process